Jean-Phillippe Courtois, a non-executive director at AstraZeneca, has spent nearly £50,000 upping his stake in the drug giant.
He bought 2,135 shares for 2,299p each and now has 2,635.
News of his purchase came on the same day AstraZeneca was celebrating a favourable decision from US regulators regarding its new drug application for diabetes treatment ONGLYZA.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee decided that the data supporting the drug application for ONGLYZA were sufficient to discount unacceptable cardiovascular risk.
Courtois, who is also the President of software company Microsoft's non-US operations, was appointed to Astra's board on February 18.
Top Director Buys
Value: £99,120
Value: £99,120
Value: £98,000
Value: £49,084
Value: £25,002
Value: £25,000
Value: £25,000
Value: £14,600
Value: £13,411
Value: £12,250
Top Director Sells
Value: £2,800,000
Value: £321,247
Value: £10,040
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
